Abstract
Arrowhead Pharmaceuticals will report fiscal third-quarter results on August 4, 2026 Post Market; consensus tracks a rebound in collaboration revenue and narrowing operating losses, with investors watching program milestones and cash burn alongside margin trends.
Market Forecast
Consensus for the current quarter anticipates Arrowhead Pharmaceuticals revenue of 54.29 million US dollars, a year-over-year increase of 128.98%, with an estimated adjusted EPS of -1.32 and EBIT of -183.73 million US dollars; year-over-year forecast growth rates imply a 28.77% improvement for EPS and a 32.72% improvement for EBIT. Last quarter’s gross profit margin stood at 100.00% and the net profit margin was -180.01%; the market expects gross margin to remain near triple-digits given collaboration revenue mix, while net losses contract year over year. The main business is expected to remain concentrated in partnered program revenue, with timing of milestones and license recognition driving the quarter. The segment with the largest upside remains partnered collaboration revenue, projected at 54.29 million US dollars this quarter, up 128.98% year over year as milestone cadence normalizes.
Last Quarter Review
In the previous quarter, Arrowhead Pharmaceuticals reported revenue of 73.74 million US dollars, a gross profit margin of 100.00%, GAAP net loss attributable to shareholders of 133.00 million US dollars, a net profit margin of -180.01%, and adjusted EPS of -0.93, with revenue declining 86.42% year over year. A notable financial highlight was cash inflow concentrated in collaboration revenue streams, maintaining 100% gross margin due to accounting for license and milestone income. Main business contributions included 41.74 million US dollars from the Sarepta collaboration, 20.47 million US dollars from Novartis, and 10.53 million US dollars from Sanofi, reflecting the company’s reliance on partnership-driven revenue.
Current Quarter Outlook
Partnered Collaboration Revenue and Milestone Timing
Arrowhead Pharmaceuticals’ primary revenue driver is collaboration and license revenue from partners. The current-quarter forecast of 54.29 million US dollars implies a sharp acceleration from the weak prior-year base, driven by expected recognition of milestones and license fees tied to partnered R&D progress. Given the company’s revenue mix, gross margin should remain close to 100.00%, but the absolute revenue is sensitive to the timing of regulatory and clinical milestones. The key watch points are program advancement events that can trigger revenue recognition and the phasing of deferred revenue into current period income. Variability is elevated because a single milestone can meaningfully shift the top line. If partner development timelines track to plan, the revenue outlook should align with consensus; any slips could lead to shortfalls despite high gross margins.
Pipeline Progress and Operating Spend
Beyond revenue recognition, investors will focus on operating spending tied to late-stage clinical programs and platform expansion. The forecast EBIT of -183.73 million US dollars suggests continued elevated R&D and SG&A outlays, though year-over-year improvement indicates cost discipline or lapping of one-off items. Management’s commentary on trial enrollment, regulatory filing timelines, and manufacturing readiness can influence expectations for future milestones and potential royalty streams. If spending growth is moderated relative to program progress, losses could narrow faster than anticipated; conversely, acceleration in clinical activity without matching collaboration inflows would pressure EBIT. Monitoring the balance between pipeline investment and external funding from partners remains central for near-term sentiment.
Stock Price Sensitivities: Milestone Cadence and Cash Runway
This quarter’s share performance is likely to hinge on two factors: the cadence of milestone recognition and the implied cash runway. With adjusted EPS expected at -1.32, any surprise on the revenue line will have a leveraged impact on margins and EPS due to high fixed operating costs. Commentary on upcoming catalysts and potential for additional upfronts or opt-in payments from partners could alleviate concerns about continued operating losses. Conversely, a gap between projected and realized milestones could raise questions about near-term funding needs and increase volatility. Clear guidance on the timing and scale of partnership revenue is therefore critical for stabilizing expectations.
Analyst Opinions
Across recent sell-side and institutional commentary, the prevailing view leans bullish, emphasizing the anticipated year-over-year rebound in revenue and improving operating trajectory. Analysts highlight that consensus embeds 54.29 million US dollars in revenue and a narrower loss profile, with upside potential tied to the timing of partner milestones and clinical progress. Positive notes from well-followed institutions underline confidence that collaboration revenue will normalize after a softer prior-year period and that operating discipline could drive sequential improvements in EBIT and EPS. The constructive stance centers on favorable risk-reward into the print, supported by high-margin revenue streams and a robust partnership network that can provide non-dilutive capital as programs advance.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments